| A case of advanced thymic carcinoma that was resected after concurrent chemoradiotherapy |
|
Hyun Woo Lim, Myung Jun Lee, Jeong Ho Park, Joo Ho Park, Sun Young Lee, Hyun Jung Jun, Do Yeun Cho |
|
전남대학교 의과대학 알레르기내과 |
| 동시적 항암화학방사선요법 시행 후 수술에 성공한 진행성 흉선암종 1예 |
|
임현우, 이명준, 박정호, 박주호, 이선영, 전현정, 조도연 |
|
Division of Allergy, Asthma and Clinical Immunology, Department of Internal Medicine, Chonnnam National University Medical School, Gwangju, Korea |
|
|
|
|
| Abstract |
|
Thymic carcinoma is a rare, but aggressive, tumor that often metastasizes to regional lymph nodes and distant sites and often has a poor prognosis. Although the efficacy of induction therapy in thymic carcinoma is unclear, we report the clinical course of a patient who underwent complete surgical resection after effective induction chemoradiotherapy. A 66-year-old man was diagnosed with a poorly differentiated thymic carcinoma (Masaoka stage III). The tumor was considered unresectable due to sternal invasion and surrounding fat infiltration. Two cycles of chemotherapy, consisting of paclitaxel (180 mg/m2 on D1) and cisplatin (80 mg/m2 on D1) combined with mediastinal radiotherapy (total 50 Gy) were performed concurrently; the mass decreased to a resectable size. Subsequently, he received adjuvant chemotherapy and adjuvant radiation therapy. He is currently alive and ambulatory and has remained disease-free for 19 months. This case demonstrates that induction chemoradiotherapy with paclitaxel and cisplatin may be tolerated and useful for patients with locally advanced thymic carcinoma. (Korean J Med 78:645-649, 2010) |
| Key Words:
Thymic carcinoma; Paclitaxel; Cisplatin; Neoadjuvant chemoradiotherapy; Surgery |
|
PDF Links
Full text via DOI
Download Citation
